Table 2.
Formulation | NAb Formation Frequency (%) | No. Publications |
---|---|---|
ABO | 0–13.3 | 621,23,25–28 |
ONA† | 0.9–5.6 | 321,26,28 |
ONA (new) | 0.3–4.0 | 323,25,27 |
ONA (old) | 7.2 | 127 |
INCO‡ | 0–1.1 | 621,23,25–28 |
Not specified | 1.9–2.5 | 221,27 |
*Estimates in these studies may be associated with either overall use or exclusive use of the BoNT-A formulations studied.
†This publication did not distinguish between the old and new formulations of ONA.
‡Most patients had previously received ABO and/or ONA.